New Hope for Alopecia Areata
A drug has been recently discussed in the Yale University news letter: “In 2014, King showed that tofacitinib, marketed as Xeljanz, could be used to treat alopecia areata. The new study confirms the validity of that report and builds a case for pursuing treatment of the disease with this and similar drugs.”
Some of my patients think that this will be used for standard genetic alopecia, but it will not
Read it here: ““This study demonstrates the drug is effective for treating alopecia areata,” said Dr. Brett A. King of Yale School of Medicine, who designed the study with Dr. Brittany Craiglow. In 2014, King showed that tofacitinib, marketed as Xeljanz, could be used to treat alopecia areata. The new study confirms the validity of that report and builds a case for pursuing treatment of the disease with this and similar drugs.”
Great to have The Balding blog “back up” again. But, as a thoughtful suggestion, why summarize studies from newspaper articles, when the actual study is publicly available to your readers through the National Library of Medicine (“Pub Med”) and can be read and interpreted for themselves:
https://www.ncbi.nlm.nih.gov/pubmed/27699252
Since these full articles (or in some cases, only the abstracts) are free of charge and, as I noted, publicly available), the mount of space to include the link would be minimal. Because many of your readers are non-scientists and don’t quite understand, in my opinion, the “nature of evidence” (ie difference between an opinion or personal anecdote vs a scientific study on a topic), it would also be an educational service.
Your effortlessness radiates through in your posts, and I am motivated by what you are doing. Your children will be fine, and they will dependably have recollections of what a solid momma they have! All the best with the hair prep. I know you will be wonderful in caps,